TY - JOUR
T1 - Exercise treatment for depression
T2 - Efficacy and dose response
AU - Dunn, Andrea L.
AU - Trivedi, Madhukar H.
AU - Kampert, James B.
AU - Clark, Camillia G.
AU - Chambliss, Heather O.
N1 - Funding Information:
We are grateful to the participants in the Depression Outcomes Study of Exercise; the Cooper Institute (CI) Scientific Advisory Board (Claude Bouchard, William L. Haskell, Norman M. Kaplan, I-Min Lee, Kiang Liu, and Guy S. Parcel); CI Community Advisory Board (Dennis Alvarez, James Race, John Hammarley, Margaret Caughy, Rene Martinez, Robert Colombe, and Sylvia Moreno); CI and University of Texas Southwestern Medical Center staff (Shannon Baker, Steven N. Blair, Beth Barlow, Janet Chandler, Tim Church, Jennifer Dodge, Michelle Edwards, Alex Jordan, Beth Leermakers, Melba Morrow, Sheila Reynolds, Erin Sinclair, Prabha Sunderajan, Samantha Underwood, Susan Wilcox, and Jody Wilkinson); and CI interns. This study was funded in part by NIMH 57031 and Technogym.
Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2005/1
Y1 - 2005/1
N2 - This study, conducted between 1998 and 2001 and analyzed in 2002 and 2003, was designed to test (1) whether exercise is an efficacious treatment for mild to moderate major depressive disorder (MDD), and (2) the dose-response relation of exercise and reduction in depressive symptoms. The study was a randomized 2x2 factorial design, plus placebo control. All exercise was performed in a supervised laboratory setting with adults (n =80) aged 20 to 45 years diagnosed with mild to moderate MDD. Participants were randomized to one of four aerobic exercise treatment groups that varied total energy expenditure (7.0 kcal/kg/week or 17.5 kcal/kg/week) and frequency (3 days/week or 5 days/week) or to exercise placebo control (3 days/week flexibility exercise). The 17.5-kcal/kg/week dose is consistent with public health recommendations for physical activity and was termed "public health dose" (PHD). The 7.0-kcal/kg/week dose was termed "low dose" (LD). The primary outcome was the score on the 17-item Hamilton Rating Scale for Depression (HRSD 17). The main effect of energy expenditure in reducing HRSD 17 scores at 12 weeks was significant. Adjusted mean HRSD 17 scores at 12 weeks were reduced 47% from baseline for PHD, compared with 30% for LD and 29% for control. There was no main effect of exercise frequency at 12 weeks. Aerobic exercise at a dose consistent with public health recommendations is an effective treatment for MDD of mild to moderate severity. A lower dose is comparable to placebo effect.
AB - This study, conducted between 1998 and 2001 and analyzed in 2002 and 2003, was designed to test (1) whether exercise is an efficacious treatment for mild to moderate major depressive disorder (MDD), and (2) the dose-response relation of exercise and reduction in depressive symptoms. The study was a randomized 2x2 factorial design, plus placebo control. All exercise was performed in a supervised laboratory setting with adults (n =80) aged 20 to 45 years diagnosed with mild to moderate MDD. Participants were randomized to one of four aerobic exercise treatment groups that varied total energy expenditure (7.0 kcal/kg/week or 17.5 kcal/kg/week) and frequency (3 days/week or 5 days/week) or to exercise placebo control (3 days/week flexibility exercise). The 17.5-kcal/kg/week dose is consistent with public health recommendations for physical activity and was termed "public health dose" (PHD). The 7.0-kcal/kg/week dose was termed "low dose" (LD). The primary outcome was the score on the 17-item Hamilton Rating Scale for Depression (HRSD 17). The main effect of energy expenditure in reducing HRSD 17 scores at 12 weeks was significant. Adjusted mean HRSD 17 scores at 12 weeks were reduced 47% from baseline for PHD, compared with 30% for LD and 29% for control. There was no main effect of exercise frequency at 12 weeks. Aerobic exercise at a dose consistent with public health recommendations is an effective treatment for MDD of mild to moderate severity. A lower dose is comparable to placebo effect.
UR - http://www.scopus.com/inward/record.url?scp=11144241830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11144241830&partnerID=8YFLogxK
U2 - 10.1016/j.amepre.2004.09.003
DO - 10.1016/j.amepre.2004.09.003
M3 - Article
C2 - 15626549
AN - SCOPUS:11144241830
SN - 0749-3797
VL - 28
SP - 1
EP - 8
JO - American Journal of Preventive Medicine
JF - American Journal of Preventive Medicine
IS - 1
ER -